Advancing Mass Spectrometry-Based Large-Cohort Proteomics for
Thursday, October 18, 2018
8 am PT, 11 am ET, 1700 CET
Large cohort studies are essential to the discovery of protein biomarkers, and their validation is indispensable to clinical utility. High-throughput and deep-proteome profiling for these studies are necessary, but they also need to generate reproducible results across different laboratories in a longitudinal mode. A high-throughput analytical workflow using high resolution MS1-based quantitative data-independent acquisition (HRMS1–DIA) mass spectrometry was standardized with well-defined experimental steps and systematically applied to a set of test samples. This Clinical OMICs webinar will highlight the objectives and outcome of this study:
- Study design to ensure benchmarking across multiple Cancer Moonshot sites worldwide utilizing similar instrument platforms, procedures, and software.
- Development and implementation of test standards and a HRMS1–DIA mass spectrometry method.
- Results of the study that demonstrate stability and reproducibility of a label-free quantitative workflow with 24/7 operation mode for seven consecutive days.
- The multi-site study also extended to a set of ovarian cancer tissue de-identified specimens for demonstrating the performance of HRMS1-DIA workflow solution in the real clinical researches.
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.?